Education
About Us
Working with TipRanks
Follow Us
Lexicon Pharmaceuticals (LXRX)
NASDAQ:LXRX
Earnings Data
Report Date
Oct 30, 2025Before Open (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.07Last Year’s EPS
-0.18Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call for Lexicon Pharmaceuticals was largely positive, marked by significant revenue growth, successful strategic repositioning to an R&D-focused company, and promising advancements in the drug pipeline. However, challenges remain in terms of reduced cash reserves and the dependence on partnerships for future progress.Company Guidance
Strong Revenue Growth
Q2 2025 revenue was $28.9 million, a significant increase from $1.6 million in Q2 2024, primarily due to $27.5 million of licensing revenue from the Novo Nordisk agreement.
Successful Strategic Pivot
Lexicon has successfully transformed into an R&D-focused company, reducing operating expenses significantly and focusing on the advancement of its innovative portfolio.
Promising Drug Development
Advancements in the pilavapadin program with the conclusion of a scientific advisory board validating the 10-milligram dose for future studies and plans for Phase III trials in DPNP.
Partnerships and Global Expansion
Viatris progressing with regulatory submissions and approvals of sotagliflozin in multiple countries, and ongoing collaboration with Novo Nordisk for LX9851.
Reduced Operating Expenses
Quarter-over-quarter operating expenses decreased by $31.9 million due to strategic repositioning and reduced marketing efforts, with full-year operating expense guidance lowered.
LXRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
LXRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 06, 2025 | $1.05 | $1.15 | +9.52% |
May 13, 2025 | $0.63 | $0.53 | -15.87% |
Mar 06, 2025 | $0.37 | $0.39 | +5.41% |
Nov 12, 2024 | $1.19 | $1.09 | -8.40% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Lexicon Pharmaceuticals (LXRX) report earnings?
Lexicon Pharmaceuticals (LXRX) is schdueled to report earning on Oct 30, 2025, Before Open (Confirmed).
What is Lexicon Pharmaceuticals (LXRX) earnings time?
Lexicon Pharmaceuticals (LXRX) earnings time is at Oct 30, 2025, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LXRX EPS forecast?
LXRX EPS forecast for the fiscal quarter 2025 (Q3) is -0.07.